---
title: "Kura Oncology posts corporate presentation on KOMZIFTI launch, ziftomenib pipeline strategy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295714112.md"
description: "Kura Oncology highlighted KOMZIFTI (ziftomenib) for NPM1-mutated AML, reporting Q2 2026 net revenue of $9.1 million, a 57% increase from Q1, with approximately 115 new patient starts. The company holds $519 million in cash and investments as of June 30, 2026, including $180 million in anticipated collaboration payments. Under its partnership with Kyowa Kirin, Kura manages 100% of U.S. sales. Funding is expected to support the ziftomenib program through Phase 3 KOMET-017 topline results anticipated in 2028."
datetime: "2026-08-12T21:48:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295714112.md)
  - [en](https://longbridge.com/en/news/295714112.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295714112.md)
---

# Kura Oncology posts corporate presentation on KOMZIFTI launch, ziftomenib pipeline strategy

-   Kura highlighted KOMZIFTI (ziftomenib) for adult relapsed or refractory NPM1-mutated AML, citing early launch momentum. \* 2Q 2026 KOMZIFTI net product revenue of USD 9.1 million, up 57% from 1Q; about 115 new patient starts. \* Cash and investments of USD 519 million as of June 30, 2026; USD 180 million of anticipated collaboration payments. \* Kyowa Kirin collaboration: 50⁄50 U.S. co-development and co-promotion; Kura books 100% U.S. sales. \* Funding expected to support the ziftomenib AML program through topline results from Phase 3 KOMET-017, anticipated in 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [KURA.US](https://longbridge.com/en/quote/KURA.US.md)
- [4151.JP](https://longbridge.com/en/quote/4151.JP.md)

## Related News & Research

- [Kura Oncology Q2 product revenue rises 57% on KOMZIFTI uptake](https://longbridge.com/en/news/295703583.md)
- [Kura Oncology CEO Troy Wilson reports purchase of 100,000 common shares worth $1.11 million](https://longbridge.com/en/news/296144763.md)
- [IMMU: Vididencel delivers durable remissions in AML and CML, with broad late-stage clinical expansion](https://longbridge.com/en/news/296462827.md)
- [IMMU: Advancing AML and CML trials, reducing costs, and preparing for U.S. pediatric expansion](https://longbridge.com/en/news/296503526.md)
- [BUZZ-Kura jumps on narrower-than-expected quarterly loss](https://longbridge.com/en/news/295816973.md)